View Older Stories View More Recent Stories
-
Telomir Pharmaceuticals (TELO) Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market
-
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market
-
Rodman & Renshaw Starts Telomir Pharma (TELO) at Buy
-
Telomir Pharmaceuticals (TELO) Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines
-
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)
-
Telomir Pharmaceuticals (TELO) Announces Breakthrough Results With Telomir-1
-
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Oth
-
Telomir Pharmaceuticals (TELO) Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria
-
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
-
Telomir Pharmaceuticals (TELO) Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
-
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
-
Telomir Pharmaceuticals (TELO) Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
-
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
-
Telomir Pharmaceuticals (TELO) Announces Reversal of Key Type 2 Diabetes Parameters
-
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
-
Telomir Pharmaceuticals (TELO) Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
-
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
-
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
-
Telomir Pharmaceuticals (TELO) Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo
-
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
-
Telomir Pharmaceuticals (TELO) Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
-
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
